What is the maximum age for giving Pediarix (DTaP‑IPV‑HepB) vaccine to children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Maximum Age for Pediarix Administration

Pediarix is licensed for use from 6 weeks of age through 6 years of age (prior to the seventh birthday), but is only indicated for the primary 3-dose series at 2,4, and 6 months of age. 1

Age Licensing vs. Clinical Indication

The FDA label establishes two distinct age parameters that must be understood:

  • Licensed age range: 6 weeks through 6 years (before the 7th birthday) 1
  • Indicated age range: Only for infants at 2,4, and 6 months as part of the primary series 2

The practical upper age limit is effectively 6 months for routine use, as Pediarix should not be used for the fourth or fifth DTaP doses (booster doses at 15-18 months and 4-6 years). 2

Key Age-Related Restrictions

Primary Series Only

  • Pediarix is specifically indicated for the first 3 doses of the DTaP series administered at 2,4, and 6 months of age. 2
  • The vaccine should not be used for booster doses at 15-18 months or 4-6 years. 2
  • The minimum age for the third dose is 24 weeks (approximately 6 months), which represents the minimum age for completing the hepatitis B vaccine series. 2

Catch-Up Vaccination

  • For catch-up purposes, Pediarix may be used in children younger than 5 years who are behind schedule, provided they still require the primary series components. 3
  • The absolute upper age limit remains prior to the seventh birthday per FDA licensing. 1

Common Pitfall: Inadvertent Booster Administration

If Pediarix is inadvertently given as a booster dose (after the primary 3-dose series) and proper spacing between previous doses was maintained:

  • The dose is considered valid and does not need to be repeated with another DTaP-containing vaccine. 2, 3
  • This applies to all vaccine components (DTaP, IPV, and Hib). 2

Clinical Context

Safety and effectiveness data for Pediarix were established in infants aged 6 weeks through 6 months based on clinical trials. 1 While the vaccine is licensed through age 6 years, there are no safety or effectiveness data for children aged 7 months through 6 years who have not previously received the vaccine. 1

References

3
Guideline

Booster and Catch‑Up Use of Pediarix

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Can Vaxelis (DTaP‑IPV‑HepB‑Hib) be initiated in a 2‑year‑old child?
What are the common and serious side effects of the Pentacel (DTaP‑IPV‑Hib) vaccine in children?
What is the approved age range for the Pentacel (DTaP‑IPV/Hib) vaccine?
Can a 15-month-old who has received three prior Pentacel (DTaP‑IPV‑Hib) doses at 2, 4, and 6 months receive the fourth booster dose now?
What is Pentacel (DTaP‑IPV/Hib combination vaccine)?
What are the treatment options for paresthesia?
How should metronidazole be dosed, administered, and monitored in newborn infants for anaerobic infections such as necrotizing enterocolitis?
In an 89‑year‑old woman taking apixaban, sotalol, perindopril, rosuvastatin, mirabegron, and venlafaxine with an estimated creatinine clearance of 68 mL/min, what is the preferred prophylaxis for urinary tract infection?
A patient with hypertension, chronic obstructive pulmonary disease, and atrial fibrillation on metoprolol 12.5 mg twice daily presents with tremor and elevated blood pressure; what management recommendations are appropriate?
What is the approved age range for the Pentacel (DTaP‑IPV/Hib) vaccine?
What are the classifications of aortic aneurysms?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.